SAN DIEGO, Calif. — November 25, 2025 — Leads & Copy — Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company focused on RAS/MAPK pathway-driven cancers, will participate in the 8th Annual Evercore Healthcare Conference at the Loews Coral Gables Hotel in Coral Gables, FL.
Management is scheduled to participate in a fireside chat on Wednesday, December 3, 2025, at 10:25 am Eastern Time. The company will also engage in one-on-one investor meetings during the conference.
A live audio webcast of the event will be available on the company’s website. An archived replay will be available for 30 days following the webcast.
Erasca’s mission is to discover, develop, and commercialize therapies for patients with RAS/MAPK pathway-driven cancers. The company was co-founded by pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for cancer treatment.
The company believes that its team’s capabilities and experience, guided by its scientific advisory board of experts in the RAS/MAPK pathway, positions it to achieve its mission of erasing cancer.
Joyce Allaire of LifeSci Advisors, LLC can be reached at jallaire@lifesciadvisors.com.
Source: Erasca, Inc.
